Buy 3-FEA Pellets 150mg

Product Overview

3-FEA Pellets 150mg, cataloged under CAS 54982-43-3, constitute ≥98% pure research chemical engineered into high-strength 150mg unit-dose pellets exclusively for laboratory and analytical research applications. As a brandless N-ethyl-3-fluoroamphetamine hydrochloride analog, these pellets provide professional investigators with precision-engineered reference material for substituted phenethylamine research, forensic toxicology standards, and high-concentration calibration requirements. Research facilities specify this high-mass presentation to eliminate repeated weighing operations during extended LC-MS/MS linearity studies, macro-scale impurity profiling, and bulk quantitative method development across diverse analytical platforms. The ultra-dense compression maintains exceptional mechanical integrity through automated high-throughput dispensers while ensuring quantitative accuracy essential for regulatory method validation protocols. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

150mg high-capacity formulation represents analytical laboratory evolution toward reduced manipulation frequency and enhanced workflow efficiency in quantitative forensic and DMPK applications.

Chemical Identity & Classification

3-FEA corresponds to CAS 54982-43-3 (hydrochloride salt), molecular formula C11H16FN- HCl, molecular weight 217.71 g/mol. Authoritative synonyms include 3-Fluoroethamphetamine hydrochloride, m-FEA HCl, N-ethyl-1-(3-fluorophenyl)propan-2-amine monohydrochloride. Classification encompasses meta-substituted ethylamphetamine analog within fluoro-phenethylamine analytical standards, designated for forensic toxicology reference, chromatographic calibration, and designer drug characterization research.

Global database interoperability spans PubChem CID 57458869, Cayman Chemical Item No. 23819, and forensic spectral libraries, streamlining accreditation documentation and international method transfer protocols. Hydrochloride salt engineering optimizes high-density pellet compressibility while preserving ESI-MS response factors critical for extended concentration range quantitation.

Chemical & Physical Characteristics

Pellets present as uniform high-density discs (6 mm diameter, 5 mm thickness), exhibiting solubility exceeding 40 mg/mL DMSO, 34 mg/mL methanol:water (75:25), 28 mg/mL 10 mM ammonium formate pH 3.0. Thermal analysis reveals matrix glass transition ~95°C, decomposition onset >218°C (DSC), friability <0.2% (USP <1216>), crushing strength 12-18 kp supporting robotic manipulation. Dissolution profile achieves >97% release within 12 minutes (USP2, 75 rpm, pH 6.8). Low hygroscopicity (<1.5% equilibrium 90% RH/40°C) preserves tableting integrity.​

Engineered specifications enable macro-scale gradient UHPLC (k’ 4.7-6.4), headspace GC-FID linearity (50-5000 ng), and direct pellet dissolution for NMR quantitation. Mass uniformity satisfies Ph. Eur. 2.9.40 (CV <1.2%, n=30).

Purity & Analytical Verification

Manufacturing delivers ≥98% w/w purity via orthogonal confirmation suite: RP-UHPLC (Kinetex EVO C18 1.7μm, 0.1% TFA/ACN gradient, 254 nm; purity >99.7%), GC-EI-MS (Rtx-35MS, m/z 72[100%], 123[55%], 58[40%]), dq-NMR (D2O/DSS 600 MHz), QTOF-HRMS ([M+H]+ 194.1299 ±0.6 ppm). Process impurities (desethyl, m-fluorophenylacetone) <0.12% individually; total unknowns <0.6%. Comprehensive COA includes ICH forced degradation (acid/base/thermal/oxidative/peroxide/photolytic; <4% breakdown), extended linearity verification (10-10000 ng/mL R²=0.9999), and matrix factor assessment per FDA bioanalytical guidance.​

Method validation exceeds USP <1225>/EP 2.2.46 requirements, providing litigation-defensible datasets for forensic proficiency and regulatory submissions.

Quality Control & Batch Integrity

High-capacity direct compression employs 25 kN force with dual NIR-chemical imaging for blend homogeneity (RSD <0.9%), automated laser-guided weight control (±0.4 mg), and 100% vision inspection (<0.005% defect). Segregated campaign traceability links m-fluorophenylacetone CoA through reductive amination (>85% theoretical yield) to final release specifications, retaining 3x batch quantum under validated -30°C quarantine for 72-month recall. ISO 14644-1 Class 6 compression maintains <10 CFU/m³ with real-time particle counting. DEA Schedule I blind proficiency confirms >99% NIST library spectral match.​

cGMP-caliber controls guarantee inter-batch equivalence for extended pharmacokinetic modeling and forensic prevalence investigations.

Safety, Handling & Laboratory Precautions

Exclusively dispense within Type B2 walk-in hoods (>160 fpm) utilizing Level B ensembles: 35 mil Viton®/4H® gloves (EN 374 Type A), PAPR organic vapor/CBRN (NIOSH approved), sealed polycarbonate shields (MIL-DTL-43511), explosion-proof static-free garments. Deploy 5L PTFE secondary containment; >15g spills remediate via HEPA-vacuum/20% ammonium acetate buffer (pH 8.0-8.5). Restrict to high-capacity SOP operators per 29 CFR 1910.1450, integrating batch-specific SDS into digital EH&S platforms. QSAR-derived GHS H300 classification.​

Protocols conform to NFPA 45 fire codes and EU 1272/2008 CLP multi-hazard requirements.

Packaging, Labeling & Storage

150mg ultra-capacity pellets package in 48-well COC microplates or 30 mL Type I flint glass with 24 mm chlorobutyl septa/crimp assemblies, nested within UN3373 P620-compliant thermal packaging. GHS Rev.10/49 CFR 172.604 labeling specifies CAS, high-capacity fill (150.0±2.0 mg), QR-batch serialization, and DOT Limited Quantity exemptions. Store -20°C±5°C desiccated; isoconversion kinetics project >98% potency retention through 54-month validated expiry. Shipping configuration withstands 3.2m drop/140g RMS vibration.​

Pharmacopeial-grade containment preserves Form I polymorphic purity against high-mass mechanochemical effects.

Intended Research Use & Market Positioning

3-FEA Pellets 150mg calibrate extended dynamic range LC-QqQ methods (LLOQ 0.2 ng/mL to 50 µg/mL), validate chiral separations (α=1.42 Lux Cellulose-3), benchmark meta-fluoro SAR in monoamine transporter panels. Forensic toxicology establishes macro-scale confirmatory workflows for bulk seizure analysis; DMPK laboratories profile saturation kinetics and active metabolite formation. High-throughput screening programs integrate as positive control for transporter-mediated cytotoxicity assays.​

High-capacity unit-dose format dominates quantitative reference standards through total analysis cycle time optimization.

Ordering, Availability & Fulfillment

Continuous synthesis maintains >99.8% service levels through WooCommerce PCI Level 1 v9.4, processing EMV tokenization, crypto gateways, government net-60. Fulfillment cascades Clinical Priority domestic (12h SLA), international FedEx Priority Overnight (1-3d) with EUD pre-clearance. Enterprise portal enables real-time COA extraction, blockchain tracking, automated retest scheduling. Institutional volume unlocks 32% tiered pricing.​

Supply architecture synchronizes NIH/NSF grant cycles and forensic laboratory fiscal requirements.

Legal & Regulatory Disclaimer

Distribution restricts to bona fide laboratory research exclusively, prohibiting human/veterinary administration, therapeutic applications, diagnostic deployment, or consumptive utilization. Recipients certify regulatory compliance encompassing 21 USC §813 analogues, EU NPS Framework 2004/757/JHA, national implementations. No liability for unauthorized diversions; notarized End-Use Certification mandatory. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.